LMD-14. Preclinical safety and activity of intraventricular Rhenium-186 Nanoliposome (186RNL) for leptomeningeal metastases

Title	LMD-14. Preclinical safety and activity of intraventricular Rhenium-186 Nanoliposome (186RNL) for leptomeningeal metastases
Authors	Maria Guerra-Garcia, Henriette Balinda, Ande Bao, Michael Garcia, Andrea Gilbert, William Phillips, John Floyd, Andrew Brenner
Magazine	Neuro-oncology Advances
Date	08/09/2021
DOI	10.1093/noajnl/vdab071.039
Introduction	Leptomeningeal metastases (LM) present significant clinical challenges, as cancer cells infiltrate the leptomeninges and cerebrospinal fluid, drastically limiting treatment options and reducing survival rates. Rhenium-186 Nanoliposome (186RNL), with its encapsulated beta emitter design, offers localised brachytherapy due to its short path length, minimising damage to nearby tissues. In this study, the maximum tolerated dose (MTD) of 186RNL was investigated through intraventricular injection in Wistar rats, testing increasing dosages. Survival rates and tumour growth were monitored, revealing significant survival benefits with 186RNL treatment and mild reactive hypertrophy as the only notable histological change.
Quote	María Teresa Guerra-García, Henriette Balinda and Ande Bao et al. LMD-14. Preclinical safety and activity of intraventricular Rhenium-186 Nanoliposome ( <sup>186</sup>RNL) for leptomeningeal metastases. 2021. DOI: 10.1093/noajnl/vdab071.039
Materials	Nanocomposites
Industry	Pharmaceutical Industry

You have successfully subscribed! Check your inbox soon to receive great emails from this sender.

NEED HELP?